Serina Therapeutics
SER
32 hedge funds and large institutions have $3.15M invested in Serina Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 9 reducing their positions, and 0 closing their positions.
19% more capital invested
Capital invested by funds: $2.66M → $3.15M (+$498K)
14% more funds holding
Funds holding: 28 → 32 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less ownership
Funds ownership: 0.36% → 0.36% (-0%)
89% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$8.78K |
| 2 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$138 |
| 3 |
SIS
Strategic Investment Solutions
Orland Park,
Illinois
|
+$92 |
| 4 |
AWM
Avior Wealth Management
Omaha,
Nebraska
|
+$23 |
| 5 |
Morgan Stanley
New York
|
+$23 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$8.8K |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$2.48K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.11K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $133 | – | – | – |
|
|
LC
27
Lindbrook Capital
Calabasas,
California
| $114 | – | – | – |
|
|
SIS
28
Strategic Investment Solutions
Orland Park,
Illinois
| $99 | +$92 | +4 | New |
|
29
BNP Paribas Financial Markets
Paris,
France
| $49 | -$161 | -7 | -78% |
|
|
30
UBS Group
Zurich,
Switzerland
| $23 | -$8.8K | -383 | -100% |
|
|
AWM
31
Avior Wealth Management
Omaha,
Nebraska
| $19 | +$23 | +1 | New |
|
|
NA
32
NewEdge Advisors
New Orleans,
Louisiana
| $1 | – | – | – |
|
|
33
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$138 | +6 | New |
|
SER Hedge Fund Activity: Q1 2023 in Review
32 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q1 2023, worth a combined $3.15M — up 19% from $2.66M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SER positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 9 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $8.78K. The largest seller was Susquehanna International Group, cutting an estimated $14.2K.
- 32 institutional investors held Serina Therapeutics (SER) as of Q1 2023, up from 28 in Q4 2022.
- Funds reported $3.15M of Serina Therapeutics stock for Q1 2023, up 19% quarter-over-quarter.
- 4 funds opened new Serina Therapeutics positions in Q1 2023 and 0 closed out, a net change of +4 holders.
- The largest Serina Therapeutics buyer in Q1 2023 was Citadel Advisors, an estimated $8.78K added.
- The largest Serina Therapeutics seller in Q1 2023 was Susquehanna International Group, an estimated $14.2K sold.
Based on aggregated 13F filings for Q1 2023.